trials

MDA Supporting More Research

MDA Supporting More Research Dr Tamar Sztal is a research fellow in the School of Biological Sciences, Monash University, primarily working on modelling muscle disease in zebrafish by investigating the role of inflammation and taurine treatment on muscle wasting in Duchenne Muscular Dystrophy. Dr Sztal and her team have developed methods to quantify both muscle [...]

Muscular Dystrophy Australia is your One-Stop-Shop

Dr Chantal Coles, Boris M Struk, Prof Kathryn North AC, and Chris Kintakis Muscular Dystrophy Australia is your one-stop-shop for expert information, support, research and trials. MDA works tirelessly to support clinical trials and expand clinical trial capacity for Australia. We have been on the Steering Committee of the National Registries for more than a [...]

FSHD Research Projects

Advertising and promoting Facioscapulohumeral dystrophy (FSHD) Research Projects Researchers at The Royal Children’s Hospital are looking for children and adolescents aged 6-18 years who have been diagnosed with FSHD, to participate in one or both of these studies: The effect of the nutritional supplement (creatine monohydrate) on strength and muscle mass in children with FSHD [...]

DMD Lifetime Mobility Scale Research Study

DMD Lifetime Mobility Scale Research Study Muscular Dystrophy Australia is assisting the UC Davis Neuromuscular Research Center in USA to seek participants for an online survey about movement and daily living abilities for people with Duchenne muscular dystrophy. The Duchenne Muscular Dystrophy Life-Time Mobility Scale (DMD-LMS) is a set of questions that ask about how [...]

Clinical trials: Your questions answered

Clinical trials: Your questions answered Promising new treatments for many muscle and nerve conditions have been developed in recent years, promising enough in fact, for pharmaceutical companies and other funding bodies to invest in expensive clinical trials. On average only about one fifth of treatments that go to clinical trial are proven to be safe [...]

FDA Approves Drug for Treatment of DMD

Chantal Coles PhD NMDRC provides a Research Update... On September 19th last year the U.S Food and Drug Administration (FDA) approved the first drug for the treatment of Duchenne Muscular Dystrophy, called EXONDYS 51™. This drug, formally known as Eteplirsen, is a gene modifying agent that bypasses a stop codon of the dystrophin, forming a [...]